Phase 2 Completed N=71 Randomized Quadruple-blind Treatment

Rosiglitazone Effect on Mitochondria and Lipoatrophy

HIV

Source: ClinicalTrials.gov NCT00367744 ↗

Enrolled (actual)

Serious AEs

39.4%

Results posted

Feb 2017

Primary outcomePrimary: Change in Limb Fat at 48 Weeks — 448; 153 grams — p=0.02

Summary

The purpose of this study is to examine the effect of rosiglitazone on limb fat and mitochondrial indices in HIV-1-infected subjects receiving stable antiretroviral therapy that does not contain stavudine (d4T) or zidovudine (AZT).

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Limb Fat at 48 Weeks	448; 153	0.02 sig
SECONDARY the Change in the Carotid IMT of the Common Carotid Artery	0.10; 0.15	—

Eligibility Criteria

Inclusion Criteria

Lipoatrophy
Thymidine sparing ARV for at least 24 weeks
Prior thymidine NRTIs for at least 12 months

Exclusion Criteria

Diabetes
Heart failure
Liver disease
Hormonal therapies

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00367744). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.